Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
RemAb Therapeutics logo — Removing harmful antibodies.

RemAb Therapeutics

Removing harmful antibodies.

Founded 2018 Spain Spain 8 employees Grant Total: $71.43K Biotechnology, Health Care

General Information

Company Name RemAb Therapeutics
Founded Year 2018
Location Spain Spain
Founders / Decision Makers
Team member Team member
Employees 8
Industries Biotechnology, Health Care
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with RemAb Therapeutics. To contact RemAb Therapeutics, visit remabtx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does RemAb Therapeutics compare?

A PDF of RemAb Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting RemAb Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About RemAb Therapeutics

RemAb Therapeutics is a biopharmaceutical company founded in 2018 with a focus on removing harmful antibodies. The company's expertise lies in the identification, characterization, and selective removal of specific antibodies using their proprietary HART-Technology. With a strong presence in Spain, RemAb Therapeutics operates in the biotechnology and healthcare industries, offering solutions in infectious diseases, allergology, autoimmunity, transplantation and transfusion medicine, as well as the modulation of human immune responses against viral vectors.

Having secured a $71.43K grant investment on 01 January 2019, RemAb Therapeutics has garnered support from notable investors such as EASME - EU Executive Agency for SMEs. The company's innovative approach to targeting specific antibodies and its diverse applications in healthcare make it a promising venture for potential investors in the biopharmaceutical sector.

Business keywords: Biopharmaceuticals, Polymeric Glycoconjugates, Nosocomial Infections, Gram-negative Infections, Healthcare Innovation, Drug Development, Immunotherapy, Antibody Treatment, Preclinical Research, Barcelona, Therapeutics, Global Commercialization, Infection Control, Immune System Modulation

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $71.43K 1
EASME - EU Executive Agency for SMEs
01 Jan 2019
Grant Undisclosed 1
EIT Health
19 Sep 2018

RemAb Therapeutics Alternatives & Competitors

View All Alternatives
RemAb Therapeutics vs
Tolerx, Inc.
Tolerx, Inc. United States

Tolerx, Inc., a world leader in immunology, has a portfolio of innovative, first-in-class drug candi...

Venture round
9 employees
Biotechnology, Health Care
RemAb Therapeutics vs
Fuse Biotherapeutics
Fuse Biotherapeutics United States

Directing and Potentiating our Immune System

Seed
6 employees
Biotechnology, Health Care
RemAb Therapeutics vs
Tridek-One
Tridek-One France

We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases

Venture round
12 employees
Biotechnology, Health Care
View all alternatives

FAQ About RemAb Therapeutics

Removing harmful antibodies.
RemAb Therapeutics was founded in 2018.
RemAb Therapeutics is headquartered in Spain.
RemAb Therapeutics operates in Biotechnology and Health Care. Its work centres on Biopharmaceuticals, Polymeric Glycoconjugates, Nosocomial Infections and Gram-negative Infections.
RemAb Therapeutics has approximately 8 employees.
RemAb Therapeutics has completed 2 funding rounds, raising a total of $71.43K. The latest funding stage is Grant.
Top alternatives and competitors to RemAb Therapeutics include Tolerx, Inc., Fuse Biotherapeutics, Tridek-One, ImCheck Therapeutics, Coley Pharmaceutical Group. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
RemAb Therapeutics and Tolerx, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for RemAb Therapeutics, https://bouncewatch.com/company/remab-therapeutics, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout